Profit before payment of interest, taxes and amortization: lilly.com (LLY)

Graphic logo of lilly.com (LLY)

Eli Lilly and Company (LLY) relies on stable, non-cyclical demand and effectively scales margins through sales growth. Total EBITDA for the period demonstrates net operating income, with the current level sitting around 46211.08. The primary catalysts are the massive interest in diabetes and obesity drugs, as well as the development of Alzheimer's disease therapies.

Eli Lilly and Company (LLY) - Operating profit EBITDA from 11/23/2025 to 11/14/2026

Lilly (LLY) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price lilly.com|LLY - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Lilly|LLY - Enterprise Value
- business book valuation details:
Equity per Share Eli Lilly|LLY - Book Capitalization|Market Capitalization to Book Value lilly.com|LLY - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Ratio Eli Lilly and Company|LLY - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Eli Lilly & Co.|LLY - Company Aggregate Debts|Debts to Book Value Eli Lilly and Company|LLY - Company Long-Term Debt|Company Short-Term Debt Eli Lilly|Interim Coverage Ratio lilly.com
- earnings and valuation multiples indicators:
LLY - Net Income|Expected Net Income Eli Lilly and Company|LLY - Price to Earnings Ratio|Future Price to Earnings Eli Lilly|LLY - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Eli Lilly and Company|LLY - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Eli Lilly|LLY - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months lilly.com|LLY - Net earnings per share growth this year|Expected net earnings per share growth next year Eli Lilly and Company
- sales revenue and business income indicators:
LLY - Company Sales|Company Future Revenue Eli Lilly and Company|LLY - P/S Multiple|Forward P/S Multiple Eli Lilly and Company
Summary company analytics:Eli Lilly and Company
Flagship merchandise of Eli Lilly

Absolute operating profit in cash terms measures the daily cash flow from core operations before depreciation and taxes. For Eli Lilly and Company (LLY), this flow is driven by the monopoly ownership of patents in diabetes and obesity therapies. By analyzing the EBITDA growth trajectory, an investor can see the actual conversion of demand into liquidity. However, regulatory pricing risks in the US could correct this trend. This indicator serves as a measure of the business's fundamental stability.

Competitors of Eli Lilly and Company (LLY)

Income before deduction of interest, taxes and amortization ABBV|AZN - Profit before payment of interest, taxes and amortization|NVS: Profit before payment of interest, taxes and amortization|MRK: Operating profit EBITDA|Operating profit before amortization NVO|AMGN (Amgen) - Operating profit EBITDA|pfizer.com (PFE) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Sanofi Aventis (SNY)|Bristol Myers Squibb - Operating profit before amortization|Operating profit EBITDA GSK (GSK Corp)|Operating profit before depreciation charges Takeda Pharmaceutical|Teva Pharmaceutical Industries Ltd. - Operating profit EBITDA|RDY (drreddys.com) - Operating profit before amortization|VTRS (Viatris) - Operating profit before deduction of amortization|Roivant - Income before deduction of interest, taxes and amortization|ZLAB (Zai Lab Ltd) - Operating profit EBITDA|Operating profit EBITDA Bausch Health Corp|Profit before payment of interest, taxes and amortization cosmosholdingsinc.com (COSM)